PolyPid Ltd. (PYPD)Healthcare | Biotechnology | Petah Tikva, Israel | NasdaqCM
5.07 USD
-0.05
(-0.977%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.17 +0.10 (1.972%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:43 a.m. EDT
The investment case here is fundamentally broken. While the company boasts a 'strong buy' analyst recommendation and a target price nearly triple the current level, these metrics ignore the reality of a biotech firm burning through cash with no path to profitability. The fundamentals are catastrophic: the stock has lost 99% of its value over five years, and the most recent annual return was a crushing -94.8%. This is not a value trap; it is a business in freefall where the market has correctly priced out the risk of permanent capital loss. The recent price uptick is merely a technical bounce off multi-year lows, not a sign of recovery. With negative free cash flow, negative equity, and no dividend to cushion the blow, there is no margin of safety. The options market confirms this despair, with traders buying deep out-of-the-money puts for 2027 expiration, betting on further declines. Until the company demonstrates sustained revenue growth and a return to positive cash flows, this remains a speculative gamble on a miracle, not an investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.081312 |
| AutoARIMA | 0.083589 |
| AutoETS | 0.084412 |
| MSTL | 0.086247 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.34 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.126 |
| Excess Kurtosis | -0.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.176 |
| Market Cap | 102,980,656 |
| Forward P/E | -4.13 |
| Beta | 1.39 |
| Website | https://www.polypid.com |
As of Aug. 22, 2026, 3:43 a.m. EDT: Speculators are heavily positioning for downside protection with massive open interest in out-of-the-money puts expiring in early 2027, while call volume remains negligible. The skew suggests a market consensus expecting further price compression rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5014663 |
| Address1 | 18 Hasivim Street |
| All Time High | 583.5 |
| All Time Low | 2.3 |
| Ask | 6.47 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 125,240 |
| Average Daily Volume3 Month | 223,450 |
| Average Volume | 223,450 |
| Average Volume10Days | 125,240 |
| Beta | 1.39 |
| Bid | 3.6 |
| Bid Size | 2 |
| Book Value | 0.265 |
| City | Petah Tikva |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.07 |
| Current Ratio | 1.346 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.13 |
| Day Low | 4.985 |
| Debt To Equity | 29.176 |
| Display Name | PolyPid |
| Earnings Call Timestamp End | 1,786,537,800 |
| Earnings Call Timestamp Start | 1,786,537,800 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -30,118,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.254 |
| Enterprise Value | 97,989,656 |
| Eps Current Year | -0.89 |
| Eps Forward | -1.2275 |
| Eps Trailing Twelve Months | -1.3 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.7995 |
| Fifty Day Average Change | 0.27050018 |
| Fifty Day Average Change Percent | 0.056360077 |
| Fifty Two Week Change Percent | 50.14663 |
| Fifty Two Week High | 5.73 |
| Fifty Two Week High Change | -0.65999985 |
| Fifty Two Week High Change Percent | -0.11518322 |
| Fifty Two Week Low | 3.06 |
| Fifty Two Week Low Change | 2.0100002 |
| Fifty Two Week Low Change Percent | 0.65686285 |
| Fifty Two Week Range | 3.06 - 5.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,593,178,200,000 |
| Float Shares | 12,163,295 |
| Forward Eps | -1.2275 |
| Forward P E | -4.1303463 |
| Free Cashflow | -17,364,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 69 |
| Fullday Change | -0.0499997 |
| Fullday Change Percent | -0.976557 |
| Fullday Price | 5.17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17789 |
| Held Percent Institutions | 0.34552 |
| Implied Shares Outstanding | 20,311,766 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-06-26 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,695,254,400 |
| Last Split Factor | 1:30 |
| Long Business Summary | PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. |
| Long Name | PolyPid Ltd. |
| Market | us_market |
| Market Cap | 102,980,656 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_49223295 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -31,501,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 103,590,006 |
| Number Of Analyst Opinions | 4 |
| Open | 5.13 |
| Operating Cashflow | -29,003,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 7 4719 5700 |
| Post Market Change | 0.099999905 |
| Post Market Change Percent | 1.9723847 |
| Post Market Price | 5.17 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 5.12 |
| Price Eps Current Year | -5.6966295 |
| Price Hint | 2 |
| Price To Book | 19.132076 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.994 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.0499997 |
| Regular Market Change Percent | -0.976557 |
| Regular Market Day High | 5.13 |
| Regular Market Day Low | 4.985 |
| Regular Market Day Range | 4.985 - 5.13 |
| Regular Market Open | 5.13 |
| Regular Market Previous Close | 5.12 |
| Regular Market Price | 5.07 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 63,535 |
| Return On Assets | -0.74625 |
| Return On Equity | -2.4359 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 20,311,766 |
| Shares Percent Shares Out | 0.0114 |
| Shares Short | 231,379 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 283,206 |
| Short Name | PolyPid Ltd. |
| Short Percent Of Float | 0.0152 |
| Short Ratio | 0.81 |
| Source Interval | 15 |
| Symbol | PYPD |
| Target High Price | 14.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 11.75 |
| Target Median Price | 12.5 |
| Total Cash | 6,563,000 |
| Total Cash Per Share | 0.323 |
| Total Debt | 1,572,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.459925 |
| Two Hundred Day Average Change | 0.610075 |
| Two Hundred Day Average Change Percent | 0.13679041 |
| Type Disp | Equity |
| Volume | 63,535 |
| Website | https://www.polypid.com |
| Zip | 4,959,376 |